+

WO2009014524A3 - Anti-microbial photodynamic therapy - Google Patents

Anti-microbial photodynamic therapy Download PDF

Info

Publication number
WO2009014524A3
WO2009014524A3 PCT/US2007/016951 US2007016951W WO2009014524A3 WO 2009014524 A3 WO2009014524 A3 WO 2009014524A3 US 2007016951 W US2007016951 W US 2007016951W WO 2009014524 A3 WO2009014524 A3 WO 2009014524A3
Authority
WO
WIPO (PCT)
Prior art keywords
ethylene glycol
glycol units
photosensitizer
vector
microorganism
Prior art date
Application number
PCT/US2007/016951
Other languages
French (fr)
Other versions
WO2009014524A2 (en
Inventor
Nikolay E. Nifantiev
Burkhard Gitter
Dmitri V. Yashunsky
Original Assignee
Ceramoptec Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/880,974 external-priority patent/US20090030257A1/en
Application filed by Ceramoptec Industries, Inc. filed Critical Ceramoptec Industries, Inc.
Priority to US12/375,241 priority Critical patent/US9216166B2/en
Priority to EP07797049.9A priority patent/EP2049105A4/en
Priority to BRPI0714667A priority patent/BRPI0714667A8/en
Priority to MX2009001074A priority patent/MX2009001074A/en
Publication of WO2009014524A2 publication Critical patent/WO2009014524A2/en
Publication of WO2009014524A3 publication Critical patent/WO2009014524A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

Antimicrobial molecular conjugates for the treatment and prevention of infectious diseases caused by pathogenic microorganisms in human and animals are provided. The key to these conjugates is a special spacer connecting at least one photosensitizer to a microorganism receptor (vector) which in turn binds selectively to the surface of a microorganism bringing about photo-destruction upon irradiation. Spacers having hydrophilic structure such as ethylene glycol units and amino carboxyl end capped ethylene glycol units must be used for linking the vector to the photosensitizer. In a preferred embodiment a spacer would have at least 3 ethylene glycol units and be end capped with a carboxyl group on one end and a amino group at the other end.
PCT/US2007/016951 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy WO2009014524A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/375,241 US9216166B2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy
EP07797049.9A EP2049105A4 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy
BRPI0714667A BRPI0714667A8 (en) 2006-07-27 2007-07-27 MOLECULAR CONJUGATE AND ITS USE
MX2009001074A MX2009001074A (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83383606P 2006-07-27 2006-07-27
US60/833,836 2006-07-27
US11/880,974 US20090030257A1 (en) 2007-07-25 2007-07-25 Anti-microbial photodynamic therapy
US11/880,974 2007-07-25

Publications (2)

Publication Number Publication Date
WO2009014524A2 WO2009014524A2 (en) 2009-01-29
WO2009014524A3 true WO2009014524A3 (en) 2020-10-15

Family

ID=40282008

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016951 WO2009014524A2 (en) 2006-07-27 2007-07-27 Anti-microbial photodynamic therapy

Country Status (4)

Country Link
EP (1) EP2049105A4 (en)
BR (1) BRPI0714667A8 (en)
MX (1) MX2009001074A (en)
WO (1) WO2009014524A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020326320A1 (en) 2019-08-02 2022-03-10 Koite Health Oy Method of enhancing the antimicrobial action of systemically administered antibiotics
CN114053406B (en) * 2021-11-23 2022-12-09 华中科技大学 Multifunctional photo-thermal nano sterilization material and preparation and application thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183245A1 (en) * 1997-03-06 2002-12-05 Tayyaba Hasan Photosensitizer conjugates for pathogen targeting
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040186087A1 (en) * 2003-03-20 2004-09-23 Ceramoptec Industries, Inc. Siderophore conjugates of photoactive dyes for photodynamic therapy
US8153111B2 (en) * 2004-06-18 2012-04-10 Ceramoptec Industries, Inc. Photo-triggered release of active substances from dendrimer-photosensitizer complexes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020183245A1 (en) * 1997-03-06 2002-12-05 Tayyaba Hasan Photosensitizer conjugates for pathogen targeting
US20030215421A1 (en) * 1999-07-21 2003-11-20 Mcdonald John R. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20020197261A1 (en) * 2001-04-26 2002-12-26 Chun Li Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
US20030176326A1 (en) * 2002-03-15 2003-09-18 Ceramoptec Industries Inc. Photosensitzers for photodynamic therapy of microbial infections
US20050153371A1 (en) * 2004-01-07 2005-07-14 Ambit Biosciences Corporation Conjugated small molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LAVI ET AL.: "The Depth of Porphyrin in a Membrane and the Membrane?s Physical Properties Affect the Photosensitizing Efficiency", BIOPHYSICAL JOURNAL, vol. 82, April 2002 (2002-04-01), pages 2101 - 2110, XP000537839 *

Also Published As

Publication number Publication date
MX2009001074A (en) 2009-06-05
EP2049105A2 (en) 2009-04-22
EP2049105A4 (en) 2022-03-30
BRPI0714667A2 (en) 2013-08-06
WO2009014524A2 (en) 2009-01-29
BRPI0714667A8 (en) 2016-10-18

Similar Documents

Publication Publication Date Title
Costley et al. Sonodynamic inactivation of Gram-positive and Gram-negative bacteria using a Rose Bengal–antimicrobial peptide conjugate
Hamblin Antimicrobial photodynamic inactivation: a bright new technique to kill resistant microbes
MX352281B (en) Glyco-substituted dihydroxy-chlorins and b-functionalized chlorins for anti-microbial photodynamic therapy.
WO2009110940A3 (en) Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use
WO2005014024A3 (en) Conjugates of a polymer and a protein linked by an oxime linking group
EP2452935A3 (en) Tetracycline derivatives for the treatment of bacterial, viral and parasitic infections
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2006093891A3 (en) Photosensitizers for targeted photodynamic therapy
BRPI0515520A (en) immunogenic composition, vaccine, methods of preparing a vaccine and preventing or treating staph infection, and use of immunogenic composition
EP2537533A3 (en) Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2005030254A3 (en) Conjugates for photodynamic therapy
WO2007023398A3 (en) Compounds for photochemotherapy
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
BRPI0410041A (en) Methods for Sinus Headache Treatment
EP2143446A4 (en) HYBRID GEL COMPRISING CHEMICALLY CROSSLINKED HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION USING THE SAME
EP2357191A3 (en) Cyclic antimicrobial peptides
ES2421731T3 (en) Composition and procedure for the treatment of MRSA
WO2008108830A3 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
EA201100413A1 (en) METHOD OF TREATING BACTERIAL INFECTION
SI1883641T1 (en) Phthalocyanine derivatives, process for their preparation, pharmaceutical compositions containing them, and their use
WO2009014524A3 (en) Anti-microbial photodynamic therapy
WO2005094554A3 (en) Therapeutic agents, methods, and treatments
WO2010125196A3 (en) Bacteriophages specific to pak and cha strains of pseudomonas aeruginosa and their applications
WO2005042699A3 (en) Modified polypeptides with therapeutic activity and methods of use
BRPI0409609A (en) reverse cholesterol transport mediators for the treatment of hypercholesterolemia

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 12375241

Country of ref document: US

Ref document number: MX/A/2009/001074

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007797049

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1068/CHENP/2009

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07797049

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: PI0714667

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090123

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载